Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Revenue (2016 - 2025)

Regenxbio has reported Revenue over the past 12 years, most recently at $30.3 million for Q4 2025.

  • Quarterly results put Revenue at $30.3 million for Q4 2025, up 43.0% from a year ago — trailing twelve months through Dec 2025 was $170.4 million (up 104.54% YoY), and the annual figure for FY2025 was $170.4 million, up 104.54%.
  • Revenue for Q4 2025 was $30.3 million at Regenxbio, up from $29.7 million in the prior quarter.
  • Over the last five years, Revenue for RGNX hit a ceiling of $398.7 million in Q4 2021 and a floor of $15.6 million in Q1 2024.
  • Median Revenue over the past 5 years was $23.2 million (2024), compared with a mean of $46.4 million.
  • Biggest five-year swings in Revenue: soared 1758.96% in 2021 and later crashed 92.14% in 2022.
  • Regenxbio's Revenue stood at $398.7 million in 2021, then crashed by 92.14% to $31.3 million in 2022, then decreased by 29.13% to $22.2 million in 2023, then fell by 4.5% to $21.2 million in 2024, then soared by 43.0% to $30.3 million in 2025.
  • The last three reported values for Revenue were $30.3 million (Q4 2025), $29.7 million (Q3 2025), and $21.4 million (Q2 2025) per Business Quant data.